Trials / Completed
CompletedNCT01564134
Dose of Hepatitis B Vaccines in Non/Low-response Populations
Effect of Dose of Hepatitis B Vaccines in Non/Low-response Populations
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 537 (actual)
- Sponsor
- Wu Jiang · Other Government
- Sex
- All
- Age
- 1 Year – 65 Years
- Healthy volunteers
- Accepted
Summary
An interventional study will be performed in subjects aged 1-65 years old to evaluate effects of different doses of hepatitis B vaccines in low or non-response population.
Detailed description
A randomized clinical study will be conducted to evaluate effects of different doses of hepatitis B vaccines in low or non-response population in China. 650 low or non-response subjects after hepatitis B vaccination will be enrolled under the premise of informed consent. 200 subjects aged 1-17 years will be divided into 3 groups and 450 subjects aged 18-65years will be divided into 4 groups. Group 1/2/3 will receive 3 doses of vaccine on day 0,30 and 180, with 5ug/10ug/20ug HBs-Ag respectively. Group 4 will receive 1 dose of vaccine with 60ug HBs-Ag, low or nonresponse subjects of which will receive the second dose by an interval of at least 28 days. All vaccinations will be done by specific study personnel, who do not take part in the assessment of safety or immunogenicity. Adverse events will be recorded after vaccination and blood samples were collected at day 30 after each vaccination for antibody detection. The clinical program approved by the ethics committee will be performed by the researchers independently. Inspectors designated by the sponsor will take meticulous on-site audits to ensure the safety specifications during the whole process of research.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | hepatitis B vaccine | hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2012-03-01
- Completion
- 2012-06-01
- First posted
- 2012-03-27
- Last updated
- 2013-07-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01564134. Inclusion in this directory is not an endorsement.